Generer rapport
Nordic Bioscience Holding A/S
Herlev Hovedgade 205, 2730 Herlev, CVR 30511271
Branche: Ikke-finansielle holdingselskaber
Virksomhedsform
Aktieselskab
Etableret
2007
Størrelse
Mikro
Ansatte
1
Omsætning
-
DKK
Bruttofortj.
-
DKK
Primært resultat (EBIT)
-1.025.230
DKK
Årets resultat
52
MDKK
Egenkapital
62
MDKK
Reklamebeskyttet virksomhed
Denne virksomhed er reklamebeskyttet. Det betyder bl.a. at oplysningerne ikke må bruges til reklamehenvendelser. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
688/95.564
"Top 10%"
Rang i Danmark
2.952/343.814
"Top 10%"
Direktion top 3
| Morten Asser Karsdal 4 | Direktør |
Bestyrelse top 3
| Bente Juel Christiansen 9 | Bestyrelsesformand |
| Henrik Bernt Sanders 40 | Bestyrelsesmedlem |
| Anders Bengt Martin Borg 1 | Bestyrelsesmedlem |
Legale ejere top 3
| 66.67-89.99% | Romarine Aps | DK |
| 10-14.99% | KKR Precision Aggregator L.P. | CA |
| 5-9.99% | Nordic Life Science Consulting Aps | DK |
Tegningsregler
Selskabet tegnes af formanden i forening med en direktør, af tre bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Stamoplysninger baseret på CVR
| Navn | Nordic Bioscience Holding A/S |
| CVR | 30511271 |
| Adresse | Herlev Hovedgade 205, 2730 Herlev |
| Branche | Ikke-finansielle holdingselskaber [642020] |
| Web | www.nordicbioscience.com |
| Etableret | 29-06-2007 (16 år) |
| Første regnskabsperiode | 29-06-2007 til 31-12-2007 |
| Virksomhedsform | Aktieselskab |
| Antal ansatte | 1 (Regnskab) |
| Reklamebeskyttelse | Ja |
| Revisor | Pricewaterhousecoopers Statsautoriseret Revisionspartnerselskab siden 25-09-2023 |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 10.616.384 DKK 9.554.746 DKK (11-04-2018 - 28-02-2021) 11.734.077 DKK (30-10-2007 - 10-04-2018) 11.884.924 DKK (29-06-2007 - 29-10-2007) |
| Vedtægter seneste | 26-01-2024 |
Medlem af brancherne
- Ikke-finansielle holdingselskaberNACE6 indeholdende 109.905 virk.
- Holdingselskabers virksomhedNACE3 indeholdende 116.399 virk.
- Pengeinstitut- og finansieringsvirksomhed undtagen forsikring og NACE2 indeholdende 149.352 virk.
- Pengeinstitut- og finansvirksomhed, forsikringNACE1 indeholdende 152.344 virk.
Formål
Selskabets formål er at drive virksomhed indenfor bioteknologi og anden dermed i forbindelse stående virksomhed, herunder udvikling, produktion og salg af diagnostiske kit samt eje datterselskaber i forbindelse hermed.
Regnskab
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | - - | - - | - - |
| Årets resultat | 51.604 -1% | 52.284 -35% | 79.886 -27% |
| Egenkapital | 62.431 -47% | 118.494 -13% | 136.416 -52% |
| Balance | 227.119 -24% | 300.395 -17% | 363.237 -26% |
Ledelsesberetning
Development in activities and financesThe Group have performed a IFRS conversion project (GAAP Analysis) to evaluate the impact of changing
accounting policies to International Financial Reporting Standards (IFRS). The analysis showed differences in two
areas: Certain development cost should be capitalized under IFRS and the historic applied revenue recognition
principle was different compared to IFRS 15. Based on this, the Group have decided to change its accounting
principles on these two areas. The change is further described in the Accounting Principles-section.
The Group has continued its activities with an increased level of activity compared to 2021. As a result, the Group reached a gross profit of DKK 243.4 million and an operating profit of DKK 82,9 million. Earnings before interest, taxes, depreciation and amortisation (EBITDA) was DKK 92,3 million compared to DKK 63,2 million in 2021. The EBITDA development is specified as follows (DKKm):
accounting policies to International Financial Reporting Standards (IFRS). The analysis showed differences in two
areas: Certain development cost should be capitalized under IFRS and the historic applied revenue recognition
principle was different compared to IFRS 15. Based on this, the Group have decided to change its accounting
principles on these two areas. The change is further described in the Accounting Principles-section.
The Group has continued its activities with an increased level of activity compared to 2021. As a result, the Group reached a gross profit of DKK 243.4 million and an operating profit of DKK 82,9 million. Earnings before interest, taxes, depreciation and amortisation (EBITDA) was DKK 92,3 million compared to DKK 63,2 million in 2021. The EBITDA development is specified as follows (DKKm):
29-06-2023